AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NEURIZON THERAPEUTICS LTD

0.078

-0.007-8.24%

Volume:1.11M

Turnover:90.22K

Market Cap:61.17M

PE:-4.43

High:0.086

Open:0.085

Low:0.075

Close:0.085

52wk High:0.165

52wk Low:0.053

Shares:784.22M

Float Shares:351.37M

Volume Ratio:1.24

T/O Rate:0.32%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.018

EPS(LYR):-0.018

ROE:-137.94%

ROA:-45.31%

PB:4.81

PE(LYR):-4.43

Loading ...

Overview Company News Filings

Neurizon Therapeutics Redeems 1 Million Convertible Notes From Obsidian for Over $1 Million; Shares Fall 8%

MT Newswires Live

Neurizon Therapeutics Secures NIH Grant to Support Investigational ALS Treatment; Shares Up 31%

MT Newswires Live

Neurizon Therapeutics Appoints Chris Bremer as Chief Executive Officer

Neurizon Therapeutics - Appoints Chris Bremer as CEO Effective 1 October 2026

THOMSON REUTERS

Neurizon Therapeutics Ltd-Neurizon Appoints Chief Executive Officer

THOMSON REUTERS

Neurizon Therapeutics Ltd-Elanco Representative Appointed as Neurizon Board Observer

THOMSON REUTERS

Neurizon Therapeutics Draws Down Over AU$8 Million Under R&D Financing Facility

MT Newswires Live

Neurizon Therapeutics Enters Strategic Research and Development Financing Facility

Neurizon Therapeutics - Executes A$17.5 Mln R&D Financing Facility with Dare Capital Loan Fund

THOMSON REUTERS

Healey ALS Platform Trial Regimen I Enrolment Completed - Topline Results for Nuz-001 Accelerated to Q2 Cy2027

THOMSON REUTERS

BUZZ-Australia's Neurizon Therapeutics jumps on deal with US firm

Neurizon Therapeutics Ltd-Neurizon Executes Long-Term Supply Agreement With Elanco

THOMSON REUTERS

Neurizon Therapeutics - to Exclusively Buy Monepantel From Elanco With Specific Alternative Rights

THOMSON REUTERS

Neurizon Therapeutics Surpasses 50% Dosing Milestone in Trial of ALS Treatment

MT Newswires Live

Neurizon to host shareholder webinar on HEALEY ALS trial recruitment expansion

Neurizon expands HEALEY ALS trial Regimen I to 240 participants

Neurizon Therapeutics Receives Ethics Approval For Phase 1 Nuz-001 Oral Liquid Formulation Study

Neurizon Therapeutics Gets Ethics Committee Nod for Neurodegenerative Disease Phase 1 Study; Shares Gain 3%

MT Newswires Live

Neurizon wins ethics approval for NUZ-001 Phase 1 oral liquid study

Neurizon Therapeutics Ltd - Receives Ethics Approval for Phase 1 Nuz-001 Oral Liquid Formulation Study

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/NUZ.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NUZ.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","market":"AU","secType":"STK","nameCN":"NEURIZON THERAPEUTICS LTD","latestPrice":0.078,"timestamp":1789020720000,"preClose":0.085,"halted":0,"volume":1111222,"delay":0,"changeRate":-0.08235294117647066,"nameEN":"NEURIZON THERAPEUTICS LTD","floatShares":351374969,"shares":784215600,"eps":-0.0176,"marketStatus":"Closed","change":-0.007,"latestTime":"09-10 16:12:00 AEST","open":0.085,"high":0.086,"low":0.075,"amount":90219,"amplitude":0.129412,"askPrice":0.083,"askSize":45000,"bidPrice":0.076,"bidSize":100000,"shortable":3,"etf":0,"ttmEps":-0.0176,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789084800000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.085,"openAndCloseTimeList":[[1788998400000,1789020000000]],"volumeRatio":1.241225,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"NUZ.AU","preClose":0.085,"auctionPrice":0.085,"auctionVolume":121500,"auctionTime":1789020002271,"referencePrice":0.078,"referenceTime":1789036203090,"auction":3,"marketStatus":"盘后竞价","timestamp":1789020002271}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","floatShares":351374969,"roa":"-45.31%","roe":"-137.94%","lyrEps":-0.0176,"volumeRatio":1.241225,"shares":784215600,"dividePrice":0,"high":0.086,"amplitude":0.129412,"preClose":0.085,"low":0.075,"week52Low":0.053,"pbRate":"4.81","psRate":"3.48","week52High":0.165,"institutionHeld":0,"latestPrice":0.078,"committee":0.37931,"eps":-0.0176,"divideRate":0,"volume":1111222,"delay":0,"ttmEps":-0.0176,"open":0.085,"prevYearClose":0.085,"prevWeekClose":0.056,"prevMonthClose":0.056,"prevQuarterClose":0.06,"fiveDayClose":0.055,"twentyDayClose":0.061,"sixtyDayClose":0.065,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NUZ.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NUZ.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NUZ.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666551483","title":"Neurizon Therapeutics Redeems 1 Million Convertible Notes From Obsidian for Over $1 Million; Shares Fall 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666551483","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666551483?lang=en_us&edition=fundamental","pubTime":"2026-09-10 10:26","pubTimestamp":1789007198,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics  agreed to redeem 1 million convertible notes held by Obsidian for a total consideration of about $1.2 million, with Obsidian agreeing not to sell Neurizon shares for two months following completion, according to a Thursday Australian bourse filing.Upon completion, Obsidian will hold 750,000 convertible notes, the filing added.Neurizon added that it remains fully funded through to the topline readout of the HEALEY ALS Platform Trial and completion of the study.The company's shares fell past 8% in recent Thursday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK7096","BK4139","BK4007","LENZ","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666301515","title":"Neurizon Therapeutics Secures NIH Grant to Support Investigational ALS Treatment; Shares Up 31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666301515","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666301515?lang=en_us&edition=fundamental","pubTime":"2026-09-09 11:09","pubTimestamp":1788923345,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics  said the US National Institutes of Health  has awarded a multimillion-dollar, multi-year grant to support an expanded access protocol  for its investigational amyotrophic lateral sclerosis  therapy NUZ-001, according to a Wednesday filing with the Australian bourse.The program is expected to provide up to 200 ALS patients who are ineligible for clinical trials with access to NUZ-001 for up to 96 weeks, alongside the ongoing phase two and three Healey ALS platform trial, per the filing.The company will serve as the regulatory sponsor and provide the drug, while the Healey and AMG Center for ALS will oversee clinical operations, the filing said.The EAP is fully funded by the NIH and is expected to involve about 20 clinical sites across the US, alongside a national virtual site, with enrolment targeted to begin in the first quarter of 2027, subject to regulatory and operational approvals, the filing added.The company's shares jumped 31% in recent Wednesday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","NUZ.AU","BK4007","BK4539","LENZ","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665986393","title":"Neurizon Therapeutics Appoints Chris Bremer as Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2665986393","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665986393?lang=en_us&edition=fundamental","pubTime":"2026-09-07 09:41","pubTimestamp":1788745278,"startTime":"0","endTime":"0","summary":"Sept 7 (Reuters) - Neurizon Therapeutics Ltd::*NEURIZON APPOINTS CHIEF EXECUTIVE OFFICER*APPOINTS CHRIS BREMER AS CEO EFFECTIVE 1 OCTOBER 2026*Further company coverage: NUZ.AX* ((reuters.briefs@thomso","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260907:nRSD5GZz4J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665367080","title":"Neurizon Therapeutics - Appoints Chris Bremer as CEO Effective 1 October 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2665367080","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665367080?lang=en_us&edition=fundamental","pubTime":"2026-09-07 07:02","pubTimestamp":1788735774,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260906:nTUETFDK1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665136772","title":"Neurizon Therapeutics Ltd-Neurizon Appoints Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2665136772","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665136772?lang=en_us&edition=fundamental","pubTime":"2026-09-07 07:02","pubTimestamp":1788735774,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260906:nTUETFDK1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659189541","title":"Neurizon Therapeutics Ltd-Elanco Representative Appointed as Neurizon Board Observer","url":"https://stock-news.laohu8.com/highlight/detail?id=2659189541","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659189541?lang=en_us&edition=fundamental","pubTime":"2026-08-13 07:46","pubTimestamp":1786578416,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUE4DVJX8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658668969","title":"Neurizon Therapeutics Draws Down Over AU$8 Million Under R&D Financing Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2658668969","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658668969?lang=en_us&edition=fundamental","pubTime":"2026-08-11 10:23","pubTimestamp":1786415025,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics  completed an initial drawdown of around AU$8.3 million under its research and development (R&D) financing facility with Dare Capital Loan Fund, secured against the company's fiscal 2026 R&D tax incentive rebate, according to a Tuesday filing with the Australian bourse.The funds will primarily support the company's continued investment in the pivotal phase two and phase three Healey ALS platform trial, which is now fully recruited and is expected to deliver results in the late second quarter of fiscal 2027, per the filing.The facility provides up to AU$17.5 million in non-dilutive funding, with annual extension options for fiscal 2027 and fiscal 2028 R&D claims, accruing interest at 1.25% per month and repayable upon receipt of the R&D tax incentive refund, the filing added.The company's shares shed nearly 2% in recent Tuesday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","NUZ.AU","BK7096","BK4539","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655337586","title":"Neurizon Therapeutics Enters Strategic Research and Development Financing Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2655337586","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655337586?lang=en_us&edition=fundamental","pubTime":"2026-07-31 14:25","pubTimestamp":1785479159,"startTime":"0","endTime":"0","summary":"BRIEF-Neurizon Therapeutics Enters Strategic Research And Development Financing FacilityJuly 31 -Neurizon Therapeutics LtdNUZ.AX:NEURIZON ENTERS STRATEGIC RESEARCH AND DEVELOPMENT FINANCING FACILITYEXECUTES A$17.5 MILLION RESEARCH AND DEVELOPMENT FINANCING FACILITY WITH DARE CAPITAL LOAN FUNDFurther company coverage:NUZ.AX","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nTUEWBQNF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655892334","title":"Neurizon Therapeutics - Executes A$17.5 Mln R&D Financing Facility with Dare Capital Loan Fund","url":"https://stock-news.laohu8.com/highlight/detail?id=2655892334","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655892334?lang=en_us&edition=fundamental","pubTime":"2026-07-31 13:21","pubTimestamp":1785475287,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nTUEWBQNF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652715994","title":"Healey ALS Platform Trial Regimen I Enrolment Completed - Topline Results for Nuz-001 Accelerated to Q2 Cy2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2652715994","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652715994?lang=en_us&edition=fundamental","pubTime":"2026-07-17 11:49","pubTimestamp":1784260141,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260717:nTUA3HW1PV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644797957","title":"BUZZ-Australia's Neurizon Therapeutics jumps on deal with US firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2644797957","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644797957?lang=en_us&edition=fundamental","pubTime":"2026-06-17 11:38","pubTimestamp":1781667507,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neurizon Therapeutics jumps on deal with US firm** Shares of biotech company Neurizon Therapeutics NUZ.AX jump 12.7% to A$0.071, their highest level since May 18** On track for best d","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nL4N42P08P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK7096","BK4561","ELAN","LU1941712348.USD","NUZ.AU","LU1941712264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644952997","title":"Neurizon Therapeutics Ltd-Neurizon Executes Long-Term Supply Agreement With Elanco","url":"https://stock-news.laohu8.com/highlight/detail?id=2644952997","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644952997?lang=en_us&edition=fundamental","pubTime":"2026-06-17 07:08","pubTimestamp":1781651280,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nTUE5MMMQF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644879521","title":"Neurizon Therapeutics - to Exclusively Buy Monepantel From Elanco With Specific Alternative Rights","url":"https://stock-news.laohu8.com/highlight/detail?id=2644879521","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644879521?lang=en_us&edition=fundamental","pubTime":"2026-06-17 07:08","pubTimestamp":1781651280,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nTUE5MMMQF:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642230058","title":"Neurizon Therapeutics Surpasses 50% Dosing Milestone in Trial of ALS Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2642230058","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642230058?lang=en_us&edition=fundamental","pubTime":"2026-06-12 08:05","pubTimestamp":1781222711,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics (ASX:NUZ) said it dosed over 50% of participants in the first regimen of a trial evaluating NUZ-001 for the treatment of amyotrophic lateral sclerosis, or ALS, according to a Fri","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4539","LENZ","BK7096","NUZ.AU","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638890966","title":"Neurizon to host shareholder webinar on HEALEY ALS trial recruitment expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2638890966","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638890966?lang=en_us&edition=fundamental","pubTime":"2026-05-27 22:55","pubTimestamp":1779893714,"startTime":"0","endTime":"0","summary":"Neurizon will host a shareholder webinar on May 28 to discuss the expansion of Regimen I in the HEALEY ALS Platform Trial.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurizon Therapeutics Ltd. published the original content used to generate this news brief on May 27, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL7qRkzs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638952980","title":"Neurizon expands HEALEY ALS trial Regimen I to 240 participants","url":"https://stock-news.laohu8.com/highlight/detail?id=2638952980","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638952980?lang=en_us&edition=fundamental","pubTime":"2026-05-27 07:42","pubTimestamp":1779838967,"startTime":"0","endTime":"0","summary":"Neurizon expanded Regimen I of the HEALEY ALS Platform Trial for NUZ-001 to 240 participants from 160.Topline results were not presented; last patient dosing is projected for Q2 2027, with topline data expected early Q3 2027.Change aims to preserve study power while producing a larger, more consistent dataset to support regulatory and partnering discussions.Cohort now set at 180 treated patients, 60 placebo controls; 113 assigned, 74 dosed as of May 22, 2026.Funding needs through completion are expected to remain unchanged, supported by philanthropic contributions, with only a modest rise in total trial cost.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurizon Therapeutics Ltd. published the original content used to generate this n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL6t9cXY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635122705","title":"Neurizon Therapeutics Receives Ethics Approval For Phase 1 Nuz-001 Oral Liquid Formulation Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2635122705","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635122705?lang=en_us&edition=fundamental","pubTime":"2026-05-13 09:57","pubTimestamp":1778637448,"startTime":"0","endTime":"0","summary":"May 13 (Reuters) - Neurizon Therapeutics Ltd ::*RECEIVES ETHICS APPROVAL FOR PHASE 1 NUZ-001 ORAL LIQUID FORMULATION STUDY*Further company coverage: NUZ.AX* ((Reuters.Briefs@thomsonreuters.com;))  ((R","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nRSD7f2kC3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635222831","title":"Neurizon Therapeutics Gets Ethics Committee Nod for Neurodegenerative Disease Phase 1 Study; Shares Gain 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635222831","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635222831?lang=en_us&edition=fundamental","pubTime":"2026-05-13 08:56","pubTimestamp":1778633814,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics  said the Bellberry Human Research Ethics Committee approved its phase 1 study to develop the NUZ-001 oral liquid formulation as a potential treatment for amyotrophic lateral sclerosis , according to a Wednesday filing with the Australian bourse.ALS is a neurodegenerative disorder associated with progressive impairment in speech and swallowing function.The phase 1 trial will enroll 32 healthy volunteers in Australia with the aim of generating safety and other data to guide formulation development and the broader program for NUZ-001, the company said.The study is scheduled to start in the third quarter and be completed in the fourth quarter.Neurizon Therapeutics shares gained 3% in recent Wednesday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","NUZ.AU","BK4539","BK4139","BK7096","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635722921","title":"Neurizon wins ethics approval for NUZ-001 Phase 1 oral liquid study","url":"https://stock-news.laohu8.com/highlight/detail?id=2635722921","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635722921?lang=en_us&edition=fundamental","pubTime":"2026-05-13 07:40","pubTimestamp":1778629242,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics received human research ethics clearance from Bellberry HREC for Phase 1 study of NUZ-001 oral liquid formulation in healthy volunteers.Trial targets start in Q3 2026, completion in Q4 2026.Study will compare oral liquid versus tablet under fed, fasted conditions to support pharmacokinetic, safety, tolerability data for ALS development program.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurizon Therapeutics Ltd. published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL4V96BT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635296162","title":"Neurizon Therapeutics Ltd - Receives Ethics Approval for Phase 1 Nuz-001 Oral Liquid Formulation Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2635296162","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635296162?lang=en_us&edition=fundamental","pubTime":"2026-05-13 07:20","pubTimestamp":1778628007,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nFWN41P1IL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":31,"code":"91000000","status":"200"}]}}